Article
New HHS Guidance for Increasing Number of Buprenorphine Clinicians Who Can Treat OUD
- Anita Silwal MS MA;
- Anna Maria South MD;
- Cindy P. Thomas PhD;
- Jeffery Talbert PhD;
- Laura C. Fanucchi, MD;
- Michelle R. Lofwall MD DFAPA DFASAM;
- Robert M. Bohler MPH MA
June 1, 2022
Does your state allow it? The ongoing opioid epidemic The U.S. hit a grim milestone of more than 100,000 drug overdose deaths,1 most opioid-involved, in the 12 months ending April 2021. This...
Article
Interpretation of the Urine Drug Screen
- Elizabeth Gillespie MD;
- John M. Cunningham, MD;
- Kimberly A. Indovina MD
May 2, 2022
Dr. Cunningham Case A 40-year-old male with depression, post-traumatic stress disorder, and chronic pain presents with somnolence and a respiratory rate of 10 breaths per minute that responded to...
Article
A different kind of leadership rounds
- Chris Moriates, MD;
- Elizabeth Schulwolf MD;
- F. Parker Hudson MD;
- Kirsten Nieto MD;
- Lysbeth Miller MD;
- Michael Pignone MD;
- Read Pierce MD
January 7, 2022
In the early 2000s, the Institute for Healthcare Improvement helped popularize the idea of Leadership WalkRounds, encouraging health care leaders to regularly visit frontline clinical units to hear...
News
Did prior authorization refusals lead to this patient’s death?
November 29, 2021
Nearly 4 years after major organizations signed a consensus statement agreeing to improve the prior authorization process, physicians say little progress has been made.
News
FDA panel votes to approve Pfizer’s vaccine for children
October 26, 2021
If the FDA follows the recommendation, as it typically does, ...the shots could be available within days.
![1]()
News
FDA panel backs second dose for Johnson & Johnson vaccine recipients
October 15, 2021
It will be up to a Centers for Disease Control and Prevention (CDC) panel to make more specific recommendations for who might need another shot.
News
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
![1]()
News
FDA OKs Pfizer COVID booster for 65 and over, those at high risk
September 23, 2021
Emerging evidence shows that booster doses of the Pfizer vaccine cause front-line immune defenders — called binding antibodies — to roughly triple soon after a person gets the third shot.
News
FDA panel backs Pfizer’s COVID booster for 65 and older, those at high risk
September 17, 2021
This followed an earlier 16-2 vote by the panel rejecting a booster dose for Americans age 16 and over.
News
Baylor gets restraining order against COVID-19 vaccine–skeptic doc
September 17, 2021
The war should be against SARS-CoV-2, but “because this virus has so many supporters, the war in essence becomes a war against ourselves, which is much harder.”